Transfer

The Helmholtz Association is pooling its commitment to prevention research with the launch of the Helmholtz Health Prevention Task Force. In a strategy paper published in Nature Medicine, the expert committee outlines initial concepts for more…

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…

In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more…

Life Science Factory Eröffnung Laborsicht

The Life Science Factory has opened its new site on the Helmholtz campus in Munich. Beginning in 2025, around 1,800 square meters of state-of-the-art laboratories and a flexible co-working space will be available for life science start-ups and…

On June 12, 2024, the National Strategy for Gene and Cell Therapies was unveiled at the Futurium in Berlin.

The X-ray of the human brain closeup image

In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…

Transfer

News

Helmholtz Launches Task Force to Strengthen Prevention Research

Start-up EBViously founded

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Life Science Factory Expands: New Innovation Hub Opens in Munich in Cooperation with Helmholtz Munich

Helmholtz Munich contributes to the National Strategy for Gene and Cell Therapies

First Patient Administered New Drug for Brain Tumor Treatment